This presentation attempts to bring the information from the previous presentation about the risks of atrial fibrillation (AFib), and the risks and benefits of the new oral anticoagulant agents that may replace warfarin, into the context of general clinical practice.

Rothman SA. Am J Med 2013; 126: 00-00.